Logo image of TSHA

TAYSHA GENE THERAPIES INC (TSHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TSHA - US8776191061 - Common Stock

5.14 USD
-0.17 (-3.2%)
Last: 1/8/2026, 6:37:45 PM
5.2 USD
+0.06 (+1.17%)
After Hours: 1/8/2026, 6:37:45 PM
Fundamental Rating

2

Overall TSHA gets a fundamental rating of 2 out of 10. We evaluated TSHA against 530 industry peers in the Biotechnology industry. While TSHA seems to be doing ok healthwise, there are quite some concerns on its profitability. TSHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TSHA had negative earnings in the past year.
TSHA had a negative operating cash flow in the past year.
In the past 5 years TSHA always reported negative net income.
TSHA had a negative operating cash flow in each of the past 5 years.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of TSHA (-31.57%) is better than 66.60% of its industry peers.
Looking at the Return On Equity, with a value of -45.63%, TSHA is in the better half of the industry, outperforming 68.30% of the companies in the same industry.
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROIC N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSHA has more shares outstanding than it did 1 year ago.
TSHA has more shares outstanding than it did 5 years ago.
TSHA has a worse debt/assets ratio than last year.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 5.91 indicates that TSHA is not in any danger for bankruptcy at the moment.
The Altman-Z score of TSHA (5.91) is better than 73.77% of its industry peers.
TSHA has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TSHA (0.23) is worse than 66.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 5.91
ROIC/WACCN/A
WACC8.82%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TSHA has a Current Ratio of 10.48. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.48, TSHA belongs to the best of the industry, outperforming 83.02% of the companies in the same industry.
TSHA has a Quick Ratio of 10.48. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.48, TSHA belongs to the top of the industry, outperforming 83.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.48
Quick Ratio 10.48
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for TSHA have decreased strongly by -152.38% in the last year.
Looking at the last year, TSHA shows a very negative growth in Revenue. The Revenue has decreased by -36.36% in the last year.
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, TSHA will show a very strong growth in Earnings Per Share. The EPS will grow by 28.07% on average per year.
The Revenue is expected to grow by 126.77% on average over the next years. This is a very strong growth
EPS Next Y-2.89%
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%
EPS Next 5Y28.07%
Revenue Next Year-20.9%
Revenue Next 2Y-27.82%
Revenue Next 3Y43.99%
Revenue Next 5Y126.77%

3.3 Evolution

TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TSHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A cheap valuation may be justified as TSHA's earnings are expected to decrease with -11.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%

More info and screens

0

5. Dividend

5.1 Amount

TSHA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (1/8/2026, 6:37:45 PM)

After market: 5.2 +0.06 (+1.17%)

5.14

-0.17 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners97.33%
Inst Owner Change0%
Ins Owners1.03%
Ins Owner Change-1.13%
Market Cap1.41B
Revenue(TTM)6.31M
Net Income(TTM)-99.93M
Analysts85.26
Price Target10.78 (109.73%)
Short Float %19.94%
Short Ratio12.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.52%
Min EPS beat(2)-9.04%
Max EPS beat(2)-0.01%
EPS beat(4)2
Avg EPS beat(4)5.88%
Min EPS beat(4)-9.04%
Max EPS beat(4)17.32%
EPS beat(8)5
Avg EPS beat(8)124.3%
EPS beat(12)7
Avg EPS beat(12)85.18%
EPS beat(16)9
Avg EPS beat(16)64.99%
Revenue beat(2)1
Avg Revenue beat(2)-39.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)21.32%
Revenue beat(4)2
Avg Revenue beat(4)-10.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)52.45%
Revenue beat(8)5
Avg Revenue beat(8)-3.64%
Revenue beat(12)8
Avg Revenue beat(12)34.16%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.91%
PT rev (3m)21.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)25.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 223.13
P/FCF N/A
P/OCF N/A
P/B 6.43
P/tB 6.43
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.02
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.9%
ROA(5y)-71.29%
ROE(3y)-6239.76%
ROE(5y)-3785.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.26%
Cap/Sales 7.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.48
Quick Ratio 10.48
Altman-Z 5.91
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)691.55%
Cap/Depr(5y)1199.42%
Cap/Sales(3y)284.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y-2.89%
EPS Next 2Y-12.26%
EPS Next 3Y-11.75%
EPS Next 5Y28.07%
Revenue 1Y (TTM)-36.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-20.9%
Revenue Next 2Y-27.82%
Revenue Next 3Y43.99%
Revenue Next 5Y126.77%
EBIT growth 1Y-23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.18%
EBIT Next 3Y40.3%
EBIT Next 5YN/A
FCF growth 1Y-76.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.7%
OCF growth 3YN/A
OCF growth 5YN/A

TAYSHA GENE THERAPIES INC / TSHA FAQ

What is the ChartMill fundamental rating of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSHA.


Can you provide the valuation status for TAYSHA GENE THERAPIES INC?

ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.


What is the profitability of TSHA stock?

TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for TAYSHA GENE THERAPIES INC?

The Earnings per Share (EPS) of TAYSHA GENE THERAPIES INC (TSHA) is expected to decline by -2.89% in the next year.